Quarta-Rad, Inc.: insider trades · United States · SEC (Form 4)

About Quarta-Rad, Inc.

Quarta-Rad, Inc. is a U.S.-based small-cap issuer incorporated in Delaware on November 29, 2011, originally as Quatra-Rad, Inc. before changing to its current name in February 2012. The company’s administrative office is located at 1201 N. Orange St., Suite 700, Wilmington, Delaware, United States. In its SEC filings, Quarta-Rad is presented as a reporting company in the United States and is currently in a transition phase rather than a mature operating platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001549631/000149315226014020/form10-k.htm)) Quarta-Rad was initially formed to distribute and sell radiation detection devices and related products to consumers and businesses in North America. For years, that legacy business centered on radiation monitors and related hardware, with inventory sourced through related-party and third-party channels. The company’s historical operating model was small, fragmented, and dependent on niche product distribution rather than on a broad direct-to-market retail franchise. Management now states that this legacy radiation detection business has been significantly reduced and is no longer a meaningful part of operations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001549631/000149315226014020/form10-k.htm)) The key investment story today is the strategic pivot toward software and artificial intelligence. Beginning in 2024, Quarta-Rad shifted its primary operational focus to Sellavir, Inc., its wholly owned subsidiary. Sellavir is an AI software company focused on advanced analytics, image processing, and call-center software solutions. Its flagship product, CenterEye, is intended to simplify the management of cloud-based call center systems through AI-driven analytics, automation, and operational monitoring capabilities. This makes the company far more technology-oriented than its historical branding might suggest. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1549631/000149315226023573/form10-q.htm)) From a competitive standpoint, Quarta-Rad does not currently appear to be a scaled platform company. Its legacy hardware business is in run-off mode, while its AI/software segment is still early-stage and appears to generate limited revenue. The company’s SEC disclosure also indicates that it is pursuing opportunities in the United States, Japan, and other international markets, with revenues presently tied primarily to a Japanese reseller relationship connected to Sellavir’s software and development services. That international orientation is relevant for investors assessing both commercial potential and customer concentration risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1549631/000149315226023573/form10-q.htm)) Recent filings underscore the transitional nature of the story. In its March 31, 2026 Form 10-Q, Quarta-Rad reported modest revenue, a net loss for the quarter, limited cash on hand, and a working-capital deficit, while noting no formal long-term bank financing arrangements. It also disclosed that the legacy radiation detection business was phased down further, whereas development and commercialization efforts for CenterEye remained the main priority. For investors, Quarta-Rad should be viewed as a U.S. technology turnaround candidate with a highly specialized niche history, a very small financial base, and execution risk that remains elevated. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1549631/000149315226023573/form10-q.htm))